A Phase 2, Randomized, Multicenter Study of Penpulimab and Anlotinib in Combination With Nab-paclitaxel Plus Gemcitabine as First-line Therapy in Patients (Pts) With Advanced Metastatic Pancreatic Cancer: PAAG.

• Status: Recruiting
• Trial end date: 2024-12-31

Summary

It is a trial to assess the efficacy and safety of Penpulimab and Anlotinib in Combination With Nab-paclitaxel Plus Gemcitabine as first-line Therapy in Patients (Pts) With Advanced Metastatic Pancreatic Cancer.

• Phase: Phase 2

Details

• Lead Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
• Collaborator: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Treatments: Gemcitabine; Paclitaxel